Aims To describe the prevalence of polypoidal choroidal vasculopathy (PCV) in a Caucasian population with neovascular age-related macular degeneration (NAMD).
Methods All patients referred to a city AMD service over a 2-year period underwent imaging including Indocyanine Green Angiography at baseline. A panel of experts confirmed the patients with NAMD and diagnosed the lesion type including PCV. The proportion of Caucasian patients with PCV was identified. Two authors independently reviewed clinical imaging and recorded data of patients with PCV on lesion characteristics. Further information including treatments received and visual acuity at different time points was analysed.
Results A total of 492 patients were diagnosed with NAMD during the 2-year study period. Of these patients, 204 had occult lesions (41.5%). PCV was identified in 45 patients (22.1% of occult NAMD and 9.1% of all NAMD). 23 patients received anti-vascular endothelial growth factor (VEGF) monotherapy, 8 received verteporfin photodynamic therapy (PDT) monotherapy and the remaining 14 patients were managed with combined PDT and anti-VEGF treatment.
Conclusions The prevalence of PCV in Caucasians is higher than previously reported. Indocyanine Green Angiography should be a standard investigation for all new patients with NAMD, particularly those with occult NAMD, to avoid missing this important subset.
- Treatment Lasers
- Diagnostic tests/Investigation
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors SY was responsible for designing data collection tools, data collection, data analysis, manuscript drafting, manuscript revision and image editing. DGP was responsible for data collection, data analysis and image editing. NAVB was responsible for study design, manuscript editing and image selection. IAP was responsible for study design, manuscript editing and is the guarantor.
Competing interests Departmental grants from Bayer and Novartis. NAVB has participated in advisory boards for Santen Pharmaceuticals and Abbvie on uveitis, Novartis on retinal vein occlusion and Alimera Sciences on DMO. IAP and NAVB have received travel expenses from Bayer to attend ophthalmology conferences. NAVB is a member of the NICE AMD Clinical Guidelines Development Committee.
Ethics approval Royal Liverpool University Hospital Audit Department.
Provenance and peer review Not commissioned; externally peer reviewed.